Video

ASCRS Live: The introduction of SeeLuma and more

Anthony Wallace, Vice President and General Manager of the US Surgical Business at Bausch + Lomb, discussed the introduction of SeeLuma, a fully digital surgical visualization platform, and more at the 2023 ASCRS annual meeting in San Diego.

Anthony Wallace, Vice President and General Manager of the US Surgical Business at Bausch + Lomb, discussed the introduction of SeeLuma, a fully digital surgical visualization platform, and more at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Anthony Wallace:

Hi everyone. My name is Anthony Wallace and I'm the Vice President and General Manager of the US Surgical Business at Bausch + Lomb. We're really excited to be here with you this week at ASCRS to share some of our latest updates that we're coming to the market with. The first is the introduction of SeeLuma. SeeLuma is our fully digital surgical visualization platform. SeeLuma offers optical surgeons a new level of visualization, compared to optical, hybrid and retrofitted microscopes. Some of the key features of SeeLuma include a heads-up 3D monitor, multiple digital display options, and an intuitive interface that really leads to outstanding surgical visualization, ergonomics, workflow, and a truly immersive educational experience. Built for the most complex surgical cases, SeeLuma is available in the United States as well as in Western Europe, and we soon plan to bring SeeLuma to additional markets in the near future.

In addition to SeeLuma, we recently announced the launch of StableVisc cohesive OVD as well as TotalVisc OVD System. TotalVisc is the only available dual-pack, cohesive and dispersive OVD in the United States that is formulated with sorbitol. Sorbitol is a chemical agent known to have excellent physical barrier capability as well as increased free radical scavenging capabilities. With the recent acquisition of AcuFocus, our portfolio now includes the Apthera IC-8 IOL. The Apthera IC-8 is the first, and only small aperture, nontoric extended depth-of-focus IOL for select cataract patients with as much as 1.5 diopters of corneal astigmatism, who wished to correct presbyopia at the same time. We're really excited about some of these updates and sharing additional information with you and we look forward to continuing our partnership and helping patients see better to live better. Thank you

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.